Authors
Latest:
Dr. Gorlick on the Challenges of Identifying Immunotherapeutic Targets in OsteosarcomasRichard Gorlick, MD, discusses the challenges of identifying immunotherapeutic targets in osteosarcomas.
Latest:
Dr. Indini on the Rationale for the PULSAR Trial in Classic Kaposi SarcomaAlice Indini, MD, discusses the rationale for the phase 2 PULSAR trial in classic Kaposi sarcoma.
Latest:
Dr. Abu-Zeinah on the Efficacy of Interferon-Alpha in Polycythemia VeraGhaith Abu-Zeinah, MD, discusses the efficacy of interferon-alpha in polycythemia vera.
Latest:
City of Hope Appoints Marcel van den Brink, MD, PhD, As President of City of Hope Los Angeles and National Medical Center, and Chief Physician ExecutiveCity of Hope announced the appointment of Marcel van den Brink, MD, PhD, as president of City of Hope Los Angeles and National Medical Center, chief physician executive and the Deana and Steve Campbell Chief Physician Executive Distinguished Chair in honor of Alexandra Levine, MD.
Latest:
Dr. Dy on the Use of Sotorasib in KRAS G12C–Mutated NSCLCGrace Dy, MD, discusses the use of sotorasib in patients with non–small cell lung cancer with KRAS G12C mutations.
Latest:
Memorial Sloan Kettering Cancer Center Launches MSKCC India to Expand Access to World-Renowned Oncologists, Cancer Care, Research, and EducationMemorial Sloan Kettering Cancer Center, the world’s oldest and largest private cancer center, has launched MSKCC India to provide cancer patients in India with access to the institution’s world-renowned oncologists, research, clinical trials, and education.
Latest:
New Cancer Study Results Confirm Lasting Effects on 9/11 First RespondersResearch investigating the physical and mental health consequences of being at the World Trade Center site during and after the terrorist attacks has been instrumental in obtaining health care coverage for thousands of individuals.
Latest:
Dr. Lees on the Utility of Genetic Testing in Ovarian CancerBrittany F. Lees, MD, discusses the utility of genetic and genomic testing in ovarian cancer.
Latest:
Dr. Binder on the Use of Immune Checkpoint Inhibitors in Endometrial Cancer TreatmentPratibha Binder, MD, discusses how the introduction of novel immune checkpoint inhibitors into frontline treatment strategies could ameliorate unmet needs in endometrial cancer.
Latest:
Dr. Gronchi on the Results of the TRASTS Trial in Soft Tissue SarcomaAlessandro Gronchi, MD, discusses the results of the phase 2 TRASTS trial in soft tissue sarcoma.
Latest:
Novel Tubulin-Targeting Therapies Make HeadwayClinical findings have recently been reported for 2 of the more advanced emerging tubulin-targeting agents, VERU-111 and plinabulin.
Latest:
Dr. Hoskins on the Impact of Race on Breast Cancer OutcomesKent Hoskins, MD, discusses the impact of race on breast cancer outcomes.
Latest:
Dr. Ayers on the Evolving Treatment Landscape in CLLEmily C. Ayers, MD, hematologist/oncologist, assistant professor, University of Virginia Health, discusses the evolving treatment landscape in chronic lymphocytic leukemia.
Latest:
Dr Grieb on the Need for Novel Biomarkers in CRCBrian C. Grieb, MD, PhD, discusses unmet needs for patients with colorectal cancer, including the identification of novel pan-CRC biomarkers for drug development.
Latest:
Narsoplimab Trial ResultsThe panel of transplant experts discuss the results of the phase 2 trial of narsoplimab and the pending FDA approval of this agent for treatment of transplant-associated of thrombotic microangiopathy.
Latest:
Dr. Sfakianos on Importance of Restaging Transurethral Resection of Bladder TumorsJohn P. Sfakianos, MD, discusses the importance of restaging transurethral resection of bladder tumors.
Latest:
Dr. Singhi on the Importance of Multidisciplinary Care With Pathologists in CancerAatur D. Singhi, MD, PhD, discusses the importance of facilitating multidisciplinary conversations that include pathologists in cancer care.
Latest:
Dr. Padrón on Biosignatures Found from a Phase 2 Study in Pancreatic CancerLacey J. Padrón, PhD, discusses biosignatures found in a phase 2 study in pancreatic cancer.
Latest:
Dr. Ehrhardt on Factors Associated with Late Mortality in Survivors of Childhood CancerMatthew J. Ehrhardt, MD, MS, discusses the link between modifiable chronic health conditions and social determinants of health with late mortality for survivors of childhood cancer.
Latest:
Dr. Lee on the Association of MSI-H, dMMR, and TMB-H Features in Endometrial CancerSarah Lee, MD, MBA, discusses the association of microsatellite instability–high, mismatch repair deficiency, and tumor mutational burden–high features in endometrial cancer.
Latest:
Final Thoughts on Case Study and Treating Multiple MyelomaDr Joseph Mikhael and expert panel re-visit the patient case and offer their final thoughts on the impact of clinical trial updates in the treatment landscape of multiple myeloma.
Latest:
Dr Wagner or the Potential Value of Immunotherapy in AngiosarcomaMichael J. Wagner, MD, explains how immunotherapy may be a promising treatment approach for patients with angiosarcoma.
Latest:
Dr Carlo-Stella on the FDA Approval of Glofitamab in Relapsed/Refractory DLBCLCarmelo Carlo-Stella, MD, PhD, discusses the FDA approval of glofitamab for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma not otherwise specified or large B-cell lymphoma arising from follicular lymphoma, after at least 2 lines of systemic therapy.
Latest:
Dr. Gradishar on the Significance of Drug Development in HER2+ Breast CancerWilliam Gradishar, MD, discusses the significance of drug development in HER2-positive breast cancer.
Latest:
Dr. Coston on the Investigation of Bone Metastases in Neuroendocrine NeoplasmsTucker Coston, MD, discusses the investigation of bone metastases in patients with well-differentiated neuroendocrine neoplasms using gallium-68 DOTATATE positron emission tomography scans.
Latest:
Dr. Collins on the Rationale for CDK4/6 Inhibitors in ER+ Breast CancerJulie M. Collins, MD, MPH, discusses the rationale for CDK4/6 inhibitors in endocrine receptor-positive breast cancer.
Latest:
Advice for Community Physicians Treating Patients with Neuroendocrine Tumor-Associated Carcinoid SyndromeDrs Das, Pommier, and Zacks share their advice for community physicians treating patients who have neuroendocrine tumors with carcinoid syndrome and carcinoid heart disease.
Latest:
Dr Hansford on the FIREFLY-1 Trial of Tovorafenib in Pediatric Low-Grade GliomaJordan Hansford, MD, discusses the phase 2 FIREFLY-1 trial, which is investigating the pan-RAF inhibitor tovorafenib (DAY101) in children and young adults with low-grade glioma.
Latest:
Dr. Nagle on Investigational Cellular Therapies in Multiple MyelomaSarah Nagle, MD, assistant professor of medicine, School of Medicine, Oregon Health & Science University, discusses investigational cellular therapies in multiple myeloma.
